Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme calls mipomersen, currently in Phase III, a blockbuster after gaining rights in potential $1.9 billion deal.

You may also be interested in...



Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro

Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.

Genzyme/Isis Gear Up For Long-awaited Kynamro Launch

Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel